Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Liabilities and Shareholders Equity Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Growth Metrics

Northwest Biotherapeutics (NWBO) Other Accumulated Expenses (2016 - 2025)

Northwest Biotherapeutics' Other Accumulated Expenses history spans 6 years, with the latest figure at $8.4 million for Q4 2025.

Quarterly results put Other Accumulated Expenses at $8.4 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $8.4 million (changed N/A YoY), and the annual figure for FY2025 was $8.4 million, changed.
Other Accumulated Expenses for Q4 2025 was $8.4 million at Northwest Biotherapeutics, up from $6.2 million in the prior quarter.
In the past five years, Other Accumulated Expenses ranged from a high of $8.4 million in Q4 2025 to a low of $8.4 million in Q4 2025.